Heritage Investors Management Corp Sells 18,196 Shares of Zoetis Inc. $ZTS

Heritage Investors Management Corp trimmed its position in Zoetis Inc. (NYSE:ZTS) by 8.9% during the third quarter, HoldingsChannel.com reports. The fund owned 186,986 shares of the company’s stock after selling 18,196 shares during the quarter. Heritage Investors Management Corp’s holdings in Zoetis were worth $13,057,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of ZTS. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Zoetis in the third quarter valued at approximately $8,169,000. Profund Advisors LLC increased its holdings in shares of Zoetis by 226.7% during the third quarter. Profund Advisors LLC now owns 25,433 shares of the company’s stock worth $1,776,000 after buying an additional 17,649 shares in the last quarter. ProShare Advisors LLC increased its holdings in shares of Zoetis by 5.6% during the third quarter. ProShare Advisors LLC now owns 115,215 shares of the company’s stock worth $8,045,000 after buying an additional 6,119 shares in the last quarter. Vise Technologies Inc. lifted its stake in shares of Zoetis by 52.9% in the 3rd quarter. Vise Technologies Inc. now owns 14,886 shares of the company’s stock valued at $1,039,000 after acquiring an additional 5,151 shares during the last quarter. Finally, Cidel Asset Management Inc. lifted its stake in shares of Zoetis by 17.5% in the 3rd quarter. Cidel Asset Management Inc. now owns 4,003 shares of the company’s stock valued at $280,000 after acquiring an additional 595 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: The FDA approved Convenia RTU, a ready-to-use, single-dose antibiotic for dogs. The product could strengthen Zoetis’ companion-animal portfolio and provide an additional commercial opportunity. FDA approves Convenia RTU ahead of Q3 results for Zoetis stock
• Positive Sentiment: Analysts expect Zoetis to potentially beat consensus estimates in its upcoming third-quarter report, with the company’s earnings setup and operating trends viewed as supportive. This is an expectation, not a reported result. Zoetis expected to beat earnings estimates
• Positive Sentiment: BTIG Research assigned a “buy” view before ending its coverage of Zoetis. The endorsement may reinforce the argument that the shares are undervalued, although the end of coverage reduces the ongoing value of that analyst relationship. BTIG Research ratings
• Neutral Sentiment: Recent market commentary highlights valuation compression versus animal-health peers IDEXX Laboratories and Elanco. Livestock and international sales have partly offset weaker U.S. pet-care demand, creating a possible recovery opportunity but not yet confirming a broad business rebound. Zoetis versus IDEXX and Elanco valuation analysis
• Negative Sentiment: Investors remain cautious because lower guidance and softer U.S. pet-care demand could limit the pace of recovery, even as the new product approval and potential earnings beat provide near-term support.

Zoetis Stock Performance

Shares of Zoetis stock opened at $79.67 on Monday. The stock has a market cap of $32.92 billion, a price-to-earnings ratio of 13.13, a P/E/G ratio of 1.18 and a beta of 0.67. Zoetis Inc. has a twelve month low of $68.77 and a twelve month high of $144.83. The company’s fifty day moving average is $75.04 and its 200 day moving average is $93.64. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. Zoetis’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period last year, the company earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.15 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. Zoetis’s dividend payout ratio is presently 34.93%.

Analysts Set New Price Targets

Several research firms recently weighed in on ZTS. Citigroup cut their price objective on Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Stifel Nicolaus dropped their target price on Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a research report on Thursday, August 20th. BTIG Research dropped coverage on Zoetis in a research report on Friday. They issued a “buy” rating for the company. Jefferies Financial Group lowered Zoetis from a “buy” rating to a “hold” rating and cut their price target for the company from $103.00 to $83.00 in a research note on Tuesday, October 20th. Finally, TD Cowen reduced their price target on Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. Six research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $93.79.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.